<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-12T07:18:46+08:00</updated>
  <subtitle>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>PD-1耐药后TLR7/8激动剂能否带来转机｜边研</title>
    <updated>2020-12-11T22:51:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/E9ExQvWmZDLrvR9xHyYH-Q</id>
    <link href="https://mp.weixin.qq.com/s/E9ExQvWmZDLrvR9xHyYH-Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺华未来五年要实现什么目标 | DRR专题·外企临床研究策略</title>
    <updated>2020-12-10T23:51:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/zLqzoMJ-gsXnEcARqLm5BA</id>
    <link href="https://mp.weixin.qq.com/s/zLqzoMJ-gsXnEcARqLm5BA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首款皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药 | 新闻稿</title>
    <updated>2020-12-10T23:51:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/5Lr-gzIIf0__gNIwORaEfw</id>
    <link href="https://mp.weixin.qq.com/s/5Lr-gzIIf0__gNIwORaEfw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>TLR激动剂能否重塑肿瘤免疫游戏规则｜边研</title>
    <updated>2020-12-09T21:18:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/V09GYRNTPJC3nejaXHMF_A</id>
    <link href="https://mp.weixin.qq.com/s/V09GYRNTPJC3nejaXHMF_A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>运营三年赴港上市，德琪医药的ACT策略 ｜ 江湖</title>
    <updated>2020-12-08T23:48:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/NMPhGI25IoHBbLnsRXWH8w</id>
    <link href="https://mp.weixin.qq.com/s/NMPhGI25IoHBbLnsRXWH8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康宁杰瑞KN026联合KN046治疗HER2阳性实体瘤Ⅱ期关键性临床研究(SEARCH-01)完成首例患者给药 | 新闻稿</title>
    <updated>2020-12-08T23:48:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/T3i80sOni8jC4UiHBGXg1g</id>
    <link href="https://mp.weixin.qq.com/s/T3i80sOni8jC4UiHBGXg1g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药与Applied BioMath启动肿瘤药理学建模战略合作 ｜ 新闻稿</title>
    <updated>2020-12-08T23:48:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/rMCFosZlGN4p3kiz94oJeg</id>
    <link href="https://mp.weixin.qq.com/s/rMCFosZlGN4p3kiz94oJeg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>20201209 本周职位精选：临床、采购 | 招聘</title>
    <updated>2020-12-08T23:48:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/iwvfn1YyQ0r-utMYqeA3Tg</id>
    <link href="https://mp.weixin.qq.com/s/iwvfn1YyQ0r-utMYqeA3Tg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药ATG-010与R-GDP联用治疗弥漫性大B细胞淋巴瘤全球多中心Ⅱ/Ⅲ期临床试验申请获受理 | 新闻稿</title>
    <updated>2020-12-07T23:00:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/pVCL1dZ4DWbo7QKVMgYbGg</id>
    <link href="https://mp.weixin.qq.com/s/pVCL1dZ4DWbo7QKVMgYbGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>思路迪医药涉足肿瘤免疫新领域 | 第一现场</title>
    <updated>2020-12-06T22:16:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/G7LM2u1Oa585hD6kCENumw</id>
    <link href="https://mp.weixin.qq.com/s/G7LM2u1Oa585hD6kCENumw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年末重磅！肿瘤免疫治疗展望和开发趋势高峰论坛广州召开｜会讯</title>
    <updated>2020-12-06T22:16:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/5tV-QxOJbSExml_hwO22aQ</id>
    <link href="https://mp.weixin.qq.com/s/5tV-QxOJbSExml_hwO22aQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>我眼中的“阿尔法折叠”｜老梁说药</title>
    <updated>2020-12-04T22:48:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/Uo5jLyHx_3wmDvNfRhrk3g</id>
    <link href="https://mp.weixin.qq.com/s/Uo5jLyHx_3wmDvNfRhrk3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首个针对HAE的单抗药物达泽优®（拉那利尤单抗注射液）获批进入中国 | 新闻稿</title>
    <updated>2020-12-04T22:48:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/Z9656mubw51oROvhXOS3KA</id>
    <link href="https://mp.weixin.qq.com/s/Z9656mubw51oROvhXOS3KA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>踩下药物警戒生态化建设的油门 | 第一现场</title>
    <updated>2020-12-03T21:58:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/wqEqCupU9Aerl5o2Ar4gHg</id>
    <link href="https://mp.weixin.qq.com/s/wqEqCupU9Aerl5o2Ar4gHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药在多个亚太市场提交XPOVIO®（Selinexor）的新药上市申请 | 新闻稿</title>
    <updated>2020-12-03T21:58:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/uiewPKHBDNdttLvlp7CuFg</id>
    <link href="https://mp.weixin.qq.com/s/uiewPKHBDNdttLvlp7CuFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>MRCT在中国（三）：对照药的国际采购｜ 客论</title>
    <updated>2020-12-02T23:00:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/_OMtYKcskT8cvzWBUrPppQ</id>
    <link href="https://mp.weixin.qq.com/s/_OMtYKcskT8cvzWBUrPppQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新法规下三类和五类化药临床研究和注册策略研讨会 | 会讯</title>
    <updated>2020-12-02T23:00:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/rlkOyP0WNtry3NfPGcjCaw</id>
    <link href="https://mp.weixin.qq.com/s/rlkOyP0WNtry3NfPGcjCaw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>MRCT在中国（二）：本土创新海外临床势如破竹 ｜ 客论</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/Nf1Usfz3W3vBkc939nMjaA</id>
    <link href="https://mp.weixin.qq.com/s/Nf1Usfz3W3vBkc939nMjaA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Selinexor III期临床研究SEAL数据在2020年结缔组织肿瘤学会年会发布并作口头报告 ｜ 新闻稿</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/u8a1eKvUmj0N9jIZ5esXEA</id>
    <link href="https://mp.weixin.qq.com/s/u8a1eKvUmj0N9jIZ5esXEA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚焦国际首创，泽生科技蝉联“中国医药企业创新100强”第一梯级 | 新闻稿</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/bwEaRVPAY7qzOm_bZVsOTQ</id>
    <link href="https://mp.weixin.qq.com/s/bwEaRVPAY7qzOm_bZVsOTQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>